Indian healthtech startup CURAPOD has raised Rs 20 crore in a pre-Series A round led by early-stage investor V3 Ventures, with participation from 3i Partners and Ideaspring Capital. The funding will support product innovation, market expansion and scaling of operations in India and select overseas markets.
Technology-driven, non‑invasive pain management
Founded in 2022 by Sri Velliyur and Surya Maguluri and operating under Litemed India, CURAPOD develops wearable medical devices for common musculoskeletal complaints such as back and knee pain, muscle stiffness, sports injuries and joint discomfort. Its flagship device uses photobiomodulation therapy—application of red and near‑infrared light—to reduce inflammation, improve microcirculation and support cellular repair.
Unlike pharmacological approaches, photobiomodulation is drug‑free and non‑invasive, making it suitable for daily use and long‑term management. The technology has growing clinical support for symptom relief and rehabilitation, positioning CURAPOD at the intersection of consumer wellness and clinical medical devices.
Planned use of funds
The Rs 20 crore infusion will be deployed across research and development, user‑experience enhancements for the companion mobile app, and expanded manufacturing capacity. CURAPOD plans to invest in data‑driven personalisation features in its app to enable better tracking, therapy tuning and adherence for users.
Operationally, the startup will scale supply‑chain capabilities and deepen direct‑to‑consumer distribution while broadening channels through online marketplaces, physiotherapy centres, hospitals, fitness centres and sports rehabilitation networks.
Domestic depth, international reach
While India remains the primary market, CURAPOD is preparing regulatory and partnership pathways for entry into regulated global markets, including Europe, where demand for clinically validated, wearable pain‑management devices is rising. The company’s dual focus aims to move it from a wellness brand to an established healthtech player with clinical credibility.
Investor perspective and market context
Investors backing the round cited confidence in CURAPOD’s technology-led approach and the sizeable, under‑served pain management segment. Chronic musculoskeletal pain is a leading contributor to disability globally, creating demand for solutions that combine clinical effectiveness with ease of use and adherence.
The deal also reflects a broader trend of increased capital flow into Indian healthtech startups that blend medical science with consumer technology, as preventive care, rehabilitation and long‑term condition management attract attention from patients, clinicians and investors alike.
With fresh capital secured, CURAPOD is entering a critical scale‑up phase, aiming to broaden access to advanced, non‑pharmacological pain management solutions across India and selected international markets.
